4.6 Article

Runx1 Is a Co-activator with FOXO3 to Mediate Transforming Growth Factor β (TGFβ)-induced Bim Transcription in Hepatic Cells

期刊

JOURNAL OF BIOLOGICAL CHEMISTRY
卷 284, 期 30, 页码 20227-20239

出版社

AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M109.027201

关键词

-

资金

  1. National Institutes of Health, NCI [CA80095 and CA55536]

向作者/读者索取更多资源

Transforming growth factor beta (TGF beta) regulates essential cellular functions such as cellular proliferation, differentiation, and apoptosis. The Bcl-2 family of proteins has been implicated as mediators of TGF beta-induced apoptosis. We demonstrated previously that TGF beta induces the expression of Bim (Bcl-2-interacting mediator of cell death), a member of the BH3-only family of proapoptotic Bcl-2 proteins, to induce cell death in B-lymphocytes. Here, we investigated the mechanism of TGF beta-mediated Bim expression in two hepatocyte cell lines that undergo apoptosis with TGF beta, AML-12 and Hep3B. We show that TGF beta induces Bimprotein and mRNA levels, and its expression is sufficient to induce cell death. Gene array results revealed that Runx1, a member of the Runx family of transcription factors, was induced by TGF beta, and this induction was confirmed at the mRNA and protein levels. Interestingly, TGF beta specifically induced the expression of Runx1 protein from an internal ribosome entry site (IRES)-dependent, cap-independent, mRNA transcript, and its overexpression was sufficient to induce hepatocyte apoptosis. Deletion and mutation analyses of the murine Bim promoter identified a putative forkhead binding element, at position -174 to -168 from the transcription start site, as the mediator of Runx1 induction. Co-immunoprecipitation, electrophoretic mobility shift assays, and chromatin immunoprecipitation assays demonstrated that Runx1 does not bind directly to the identified forkhead binding element but rather binds the transcriptional regulator FOXO3, which occupies this site. Finally, small interfering RNA knockdown of Runx1 or FOXO3 decreased TGF beta-induced Bim expression. Our results support a mechanism in which TGF beta stimulates Bim transcription by up-regulating Runx1 expression, which binds FOXO3, and the two cooperate in the transcriptional induction of Bim.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

CD30 Is a Potential Therapeutic Target in Malignant Mesothelioma

Snehal Dabir, Adam Kresak, Michael Yang, Pingfu Fu, Gary Wildey, Afshin Dowlati

MOLECULAR CANCER THERAPEUTICS (2015)

Article Cell Biology

Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263

E. F. Greenberg, K. S. McColl, F. Zhong, G. Wildey, A. Dowlati, C. W. Distelhorst

CELL DEATH & DISEASE (2015)

Article Oncology

PIAS3 expression in squamous cell lung cancer is low and predicts overall survival

Rime Abbas, Karen S. McColl, Adam Kresak, Michael Yang, Yanwen Chen, Pingfu Fu, Gary Wildey, Afshin Dowlati

CANCER MEDICINE (2015)

Article Oncology

Clinical correlation of extensive-stage small-cell lung cancer genomics

A. Dowlati, M. B. Lipka, K. McColl, S. Dabir, M. Behtaj, A. Kresak, A. Miron, M. Yang, N. Sharma, P. Fu, G. Wildey

ANNALS OF ONCOLOGY (2016)

Article Oncology

RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR

Nneha Sakre, Gary Wildey, Mohadese Behtaj, Adam Kresak, Michael Yang, Pingfu Fu, Afshin Dowlati

ONCOTARGET (2017)

Article Oncology

Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance)

Arnaud Augert, Qing Zhang, Breanna Bates, Min Cui, Xiaofei Wang, Gary Wildey, Afshin Dowlati, David MacPherson

JOURNAL OF THORACIC ONCOLOGY (2017)

Article Oncology

Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer

Karen McColl, Gary Wildey, Nneha Sakre, Mary Beth Lipka, Mohadese Behtaj, Adam Kresak, Yanwen Chen, Michael Yang, Vamsidhar Velcheti, Pingfu Fu, Afshin Dowlati

ONCOTARGET (2017)

Article Oncology

The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells

Sarmishtha De, Daniel J. Lindner, Claire J. Coleman, Gary Wildey, Afshin Dowlati, George R. Stark

CANCER RESEARCH (2018)

Article Oncology

PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status

Snehal Dabir, Amy Kluge, Karen McColl, Yu Liu, Minh Lam, Balazs Halmos, Gary Wildey, Afshin Dowlati

INTERNATIONAL JOURNAL OF CANCER (2014)

Article Oncology

Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma

Tian He, Karen McColl, Nneha Sakre, Yanwen Chen, Gary Wildey, Afshin Dowlati

MOLECULAR ONCOLOGY (2018)

Article Oncology

Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer

Priyanka Bhateja, Michelle Chiu, Gary Wildey, Mary Beth Lipka, Pingfu Fu, Michael Chiu Lee Yang, Fatemeh Ardeshir-Larijani, Neelesh Sharma, Afshin Dowlati

CANCER MEDICINE (2019)

Article Oncology

Identification of RUNX1T1 as a potential epigenetic modifier in small-cell lung cancer

Tian He, Gary Wildey, Karen McColl, Alyssa Savadelis, Kyle Spainhower, Cassidy McColl, Adam Kresak, Aik Choon Tan, Michael Yang, Ata Abbas, Afshin Dowlati

Summary: RUNX1T1 gene amplification was specific to small cell tumors of c-SCLC patients but rare in 'pure' SCLC patients. Higher expression of RUNX1T1 was observed in SCLC compared to other cancers, including NSCLC. Additionally, stable RUNX1T1 overexpression led to significant changes in E2F targets and decreased CDKN1A (p21) expression in multiple lung cancer cell lines.

MOLECULAR ONCOLOGY (2021)

Article Oncology

CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer

Daniel J. Lindner, Gary Wildey, Yvonne Parker, Afshin Dowlati, George R. Stark, De Sarmishtha

Summary: The study investigated the potential effect of combining Rova-T and CBL in small cell lung cancer to eradicate tumor-initiating cells more effectively, presenting a novel therapeutic strategy for increasing survival rates in SCLC patients.

BRITISH JOURNAL OF CANCER (2021)

Article Oncology

Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer

Gary Wildey, Ashley M. Shay, Karen S. McColl, Suzy Yoon, Mohammad A. Shatat, Ahmad Perwez, Kyle B. Spainhower, Adam M. Kresak, MaryBeth Lipka, Michael Yang, Mohadese Behtaj, Pingfu Fu, Asrar Alahmadi, Wadad Mneimneh, Ata Abbas, Afshin Dowlati

Summary: Genomic studies have found that some small cell lung cancer (SCLC) tumors do not have RB1 mutations, contrary to the canonical model. This study examined RB1 protein expression and its function in SCLC and found that 14% of SCLC tumors expressed abundant RB1 protein, which was associated with neuroendocrine gene expression and enriched in YAP1 expression. SCLC cells with RB1 protein expression were sensitive to growth inhibition by the CDK4/6 inhibitor palbociclib, and a patient with wild-type RB1 SCLC showed a significant decrease in mutant TP53 ctDNA allelic fraction and tumor mass after treatment with the CDK4/6 inhibitor abemaciclib.

MOLECULAR CANCER THERAPEUTICS (2023)

Editorial Material Oncology

Genomic alterations in small cell lung cancer and their clinical relevance

Gary Wildey, Afshin Dowlati

TRANSLATIONAL LUNG CANCER RESEARCH (2016)

暂无数据